HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SI
SHOULDER INNOVATIONS, INC.
There isn't enough reported data to score SI yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
SI's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SI PE Valuation
SI has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
SI has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2025 | -$0.83 | -$0.20 |
| Q4 2024 | -$0.78 | -$0.14 |
SI has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SI on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SI on profitability, with a higher operating margin.
SI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16.2M | +38% |
| Q2 2026 | $17.2M | +56% |
| Q1 2026 | $16.7M | +65% |
| Q4 2025 | $14.4M | +65% |
| Q3 2025 | $11.8M | +58% |
| Q2 2025 | $11M | +33% |
| Q1 2025 | $10.1M | +41% |
| Q4 2024 | $8.7M | +28% |
SI's revenue has grown year over year every quarter since early 2024: $16M last quarter, up 38% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -47% | +18 points |
| Q2 2026 | -58% | -5.2 points |
| Q1 2026 | -54% | -11 points |
| Q4 2025 | -59% | -18 points |
| Q3 2025 | -65% | -13 points |
| Q2 2025 | -53% | -5 points |
| Q1 2025 | -42% | +2.9 points |
| Q4 2024 | -41% | -5.3 points |
SI's operating margin was −47% last quarter, up 18 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
SI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7M | +$4.4M |
| Q1 2026 | -$15.1M | -$7.8M |
| Q1 2025 | -$7.3M | -$2.5M |
SI has burned cash in almost every quarter: −$43M over the past year, against −$27M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +109K shares |
| 1 year | +4.6% | +921K shares |
| 3 years | +4.6% | +921K shares |
SI has 21M diluted shares, up 4.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q2 2024 | — |
| Q1 2024 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SI Net Leverage
SI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 52.6 | Neutral |
SI's weekly RSI is 57 (neutral) and its Stochastic is 53 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SI PE vs Healthcare Sector
SI has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
SI has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus SI above 3 of 3.
SI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.1 | 10% above |
| 20 week MA | $20.0 | 5.3% above |
| 50 week MA | $16.9 | 25% above |
SI is in an uptrend: it's above all three of its weekly moving averages, and 25% above its 50-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $14.3 | $15.3 | +7% |
| 2026 YTD | $15.3 | $21.1 | +38% |
SI has the edge over HIMS on returns for 2026, with the stronger performance.